Back

Potential real-world benefit of semaglutide 2.4 mg on cardiovascular outcomes in the UK based on the SELECT trial

31 August 2025 (17:40 - 17:50)
Organised by: Logo
Congress Presentation Part of: Using big data to drive cardiovascular innovations Electronic Health Records & Hospital Information Systems ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Francesco Fusco

Copenhagen (Denmark)

5 More presentations in this session

Presentation thumbnail
The continuity of care in primary care improves prognosis in patients referred to a cardiology department
Doctor J. Gonzalez Juanatey (Santiago de Compostela, ES)
Abstract Slides Video
Presentation thumbnail
Development and implementation of a heart failure dashboard for England: nationwide analysis of 1.4 million primary and secondary health care records
Professor C. Gale (Leeds, GB)
Abstract Slides Video
Presentation thumbnail
Comparative clinical outcomes on renal function and mortality of uricosuric agents versus xanthine oxidase inhibitors in patients with hyperuricemia and cardiovascular risks
Doctor A. Wada (Kusatsu, JP)
Abstract Slides Video
Presentation thumbnail
Development and validation of a nomogram model for all-cause mortality risk in patients with acute myocardial infarction complicated by impaired activity daily living
Doctor Y. Zhang (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Clinical profiles and temporal trends of 37,741 cardiovascular hospitalizations in greece over 13 years: initial insights from the CardioMining-AI nationwide database
Doctor A. Samaras (Thessaloniki, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Using big data to drive cardiovascular innovations
Video

The Event

Event poster

ESC Congress 2025

31 August 2025 17:40 CET
You may be interested in
thumbnail
Congress Presentation
Cost-effectiveness of semaglutide for secondary prevention of cardiovascular disease in the United States
thumbnail
Congress Session
Using big data to drive cardiovascular innovations
thumbnail
Congress Session
What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources